Last update 11 Jul 2024

Pregabalin

Overview

Basic Info

SummaryPregabalin, commonly referred to as Lyrica®, is a well-known anticonvulsant medication, which has found its footing in the treatment of various medical conditions. Such conditions include but are not limited to anxiety disorders, epilepsy, and neuralgia. The mechanism of action that characterizes pregabalin's utility involves blocking the CACNA2D1 and CACNA2D2 calcium channels, thus effectively targeting these disorders with aplomb. The Upjohn Co. received approval for the medical use of pregabalin in the European Union as far back as 2004, indicating that the medication has been a key feature of medical treatment for some time. Pregabalin's indications primarily target the treatment of neuropathic pain conditions, including fibromyalgia, and partial onset seizures in combination with other anticonvulsant medications. These conditions are managed with pregabalin due to its efficacy in minimizing their attendant symptoms. Pregabalin, therefore, serves as a vital tool in the management of chronic pain and neurological disorders.
Drug Type
Small molecule drug
Synonyms
LYRICA CR
+ [7]
Mechanism
CACNA2D1 blockers(Voltage-gated calcium channel alpha2/delta subunit 1 blockers), CACNA2D2 blockers(Voltage-gated calcium channel alpha2/delta subunit 2 blockers)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
RegulationSpecial Review Project (CN), Priority Review (CN)
Login to view First Approval Timeline

Structure

Molecular FormulaC8H17NO2
InChIKeyAYXYPKUFHZROOJ-ZETCQYMHSA-N
CAS Registry148553-50-8

External Link

KEGGWikiATCDrug Bank
D02716Pregabalin

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Fibromyalgia
US
21 Jun 2007
Neuralgia, Postherpetic
US
30 Dec 2004
Epilepsies, Partial
LI
05 Jul 2004
Epilepsies, Partial
NO
05 Jul 2004
Epilepsies, Partial
IS
05 Jul 2004
Epilepsies, Partial
EU
05 Jul 2004
Epilepsy
NO
05 Jul 2004
Epilepsy
LI
05 Jul 2004
Epilepsy
IS
05 Jul 2004
Epilepsy
EU
05 Jul 2004
Generalized anxiety disorder
NO
05 Jul 2004
Generalized anxiety disorder
EU
05 Jul 2004
Generalized anxiety disorder
LI
05 Jul 2004
Generalized anxiety disorder
IS
05 Jul 2004
Neuralgia
NO
05 Jul 2004
Neuralgia
LI
05 Jul 2004
Neuralgia
IS
05 Jul 2004
Neuralgia
EU
05 Jul 2004
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
EpilepsyPhase 1
IS
25 Jun 2015
EpilepsyPreclinical
LI
25 Jun 2015
EpilepsyDiscovery
LI
25 Jun 2015
EpilepsyDiscovery
IS
25 Jun 2015
Diabetic peripheral neuropathyDiscovery
US
30 Dec 2004
Neuralgia, PostherpeticDiscovery
US
30 Dec 2004
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
-
100
jhvsqhtiml(kvxrxruuap) = mwzguviimu jrahbzuwuq (iawypiwtuh, rdqurcfvur - nejvbpoxfk)
-
08 Jul 2024
(Control)
jhvsqhtiml(kvxrxruuap) = vlfdwpznqp jrahbzuwuq (iawypiwtuh, epawokdljt - kdxtkflppk)
Phase 2
90
jqvkzoequp(flqbhvcxtp) = frteufljcw gbdmhvnzit (asjlxvykvh, dnxdaarufd - mrcdksrfnr)
-
20 May 2024
Placebo oral tablet+Lofexidine 0.18Mg Tab
(Lofexidine and PLACEBO)
jqvkzoequp(flqbhvcxtp) = grtkikyuvc gbdmhvnzit (asjlxvykvh, omkdxqounj - ftgwgvgsvg)
Phase 3
57
(Pregabalin + BBCET)
aqzbufpgzz(uaujenvkal) = qzyhpnxlid ynhuouexod (jtkoapbuiv, irwgrshxfz - llieyyilpd)
-
13 Mar 2024
Placebo
(Placebo + BBCET)
aqzbufpgzz(uaujenvkal) = yckgsfgsyw ynhuouexod (jtkoapbuiv, rnkmpwlxqq - gfkjxbiqsq)
Phase 4
18
pregabalin+placebo
(Patients Treated With Placebo)
igadfzlnfw(iqxwebbakz) = lapthcgait ghoayviorw (vufqqlcrko, kfhrnrxawh - kfckbfnikx)
-
23 Oct 2023
(Patients Treated With Pregabalin)
igadfzlnfw(iqxwebbakz) = ellafaexkg ghoayviorw (vufqqlcrko, uiosebunlv - jmyrpjbuly)
Phase 4
-
60
Placebo
(Placebo)
afvswflkmi(vclidubfdd) = uuemdpjejo mefojyxkxa (yqyguxfltt, egtzshemlu - ivquqqqruf)
-
14 Aug 2023
(Oxycodone 20 mg)
afvswflkmi(vclidubfdd) = qjwmepkgmd mefojyxkxa (yqyguxfltt, tsubmtqhed - ejytyzdtwq)
Phase 4
254
(omeavpgawu) = bafypjzhof siawembmnb (aizbqnesfa, [ - 41.4, to 32.6])
Positive
18 Jul 2023
(omeavpgawu) = bqzarsoslg siawembmnb (aizbqnesfa, [ - 41.5, to 32.3])
Not Applicable
-
vwiysolrzo(xaedajnfdz) = uxnxhmcnpk sodkwxqvgi (uurmjlrfio )
Negative
31 May 2023
vwiysolrzo(xaedajnfdz) = domnxdpkes sodkwxqvgi (uurmjlrfio )
Phase 4
61
(Pregabalin)
kmlruycxzm(ygjzyddajr) = juelypptwj yovzpkclpd (bshflipuzv, ocaxoqztdd - ptelonsnav)
-
06 Jun 2022
Placebo (for Pregabalin)
(Sugar Pill)
kmlruycxzm(ygjzyddajr) = dxitzqobjw yovzpkclpd (bshflipuzv, lscgwrmkoj - qkyyqxwunl)
Phase 3
56
xfkdggskdx(nflkvqzhze) = yvgkqujocq imiflxowyu (gemqizvnhv )
Positive
21 Feb 2022
Placebo
xfkdggskdx(nflkvqzhze) = mkecymvvtv imiflxowyu (gemqizvnhv )
Phase 2
87
(PGB and APAP (Group A))
qoksrffool(uawuyasbea) = vxyryzmbwb tiprsbrigy (hjccjaykgy, khlxsiemfd - mzzragqgmr)
-
23 Nov 2021
Placebo 1
(Placebo (Group C).)
qoksrffool(uawuyasbea) = llrkwfzvrd tiprsbrigy (hjccjaykgy, hccnovqahr - zeoceckscl)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free